查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1790442

溶小體儲積症治療市場規模、佔有率和趨勢分析報告：按治療類型、疾病類型、地區和細分市場預測，2025 年至 2033 年

Lysosomal Storage Disease Treatment Market Size, Share & Trends Analysis Report By Treatment Type (Enzyme Replacement Therapy, Substrate Reduction Therapy), By Disease Type, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

溶小體儲積症治療市場摘要

全球溶小體儲積症治療市場規模預計在2024年達到45.4億美元，預計2025年至2033年期間的複合年成長率為4.54%，到2033年將達到66.8億美元。這得益於診斷能力的提升、酵素替代療法和基因療法的進步以及對罕見遺傳疾病認知的提高。溶小體儲積症(LSD) 治療市場正穩定成長，這得益於研發舉措的不斷擴展以及對罕見遺傳疾病認知的不斷提高。

大量的研發投入正在推動治療方法的進步，並有助於滿足尚未滿足的醫療需求。美國國家醫學圖書館於 2022 年 7 月發表的一項研究發現，LSD 的盛行率比先前認為的更高，總體發生率為 1/5,000 到 1/8,000。該研究也強調了種族和地區對盛行率的影響。例如，在一般人群中，高雪氏症的發生率為 1/40,000 到 1/60,000，但在阿什肯納茲猶太人中，這一比例上升到 1/800。同樣，泰-薩克斯病和 A 型尼曼-匹克病在該族群中很常見，天冬胺酸葡萄糖胺尿症在芬蘭人中很常見，發生率為 1/18,500。這些盛行率的上升凸顯了對有效治療方法日益成長的需求，從而推動了市場擴張。

隨著創新治療方法的推出，LSD 治療市場預計將進一步加強。在全球研發支出不斷增加的支持下，各公司都在積極進行開發新藥。例如，2021 年 2 月，Genethon 與 Spark Therapeutics 合作，利用其專有技術啟動了一項針對遲發性龐貝病的基因治療臨床試驗。同時，宣傳宣傳活動正在獲得動力，並在改善患者預後方面發揮關鍵作用。在美國和英國等國家，透過國家法布瑞氏症基金會 (NFDF)、法布瑞國際網路、澳洲法布瑞氏症和英國MPS 協會推動的每年 4 月的「法布瑞氏症宣傳月」等舉措，人們對法布瑞氏症的認知已顯著提高。

目錄

第1章調查方法與範圍

第2章執行摘要

第3章溶小體儲積症（LSD）治療市場變數、趨勢與範圍

  • 市場體系展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 商業環境分析
    • 產業分析-波特五力分析
    • PESTLE分析
    • 管道分析
    • 專利到期分析
    • 定價分析

第4章溶小體儲積症（LSD）治療市場：依治療類型分類的業務分析

  • 2025 年和 2033 年治療類型市場佔有率
  • 治療類型細分儀表板
  • 按治療類型分類的市場規模、預測和趨勢分析（2021-2033 年）
  • 酵素替代療法
  • 基材還原療法

第5章溶小體儲積症（LSD）治療市場：依疾病類型分類的業務分析

  • 2025 年及 2033 年各疾病類型的市場佔有率
  • 疾病類型細分儀表板
  • 市場規模、預測與趨勢分析（按疾病類型，2021-2033 年）
  • 高雪氏症
  • 黏多醣症
  • 龐貝氏症
  • 法布瑞氏症
  • 其他

第6章溶小體儲積症（LSD）治療市場：區域估計與趨勢分析

  • 2025年及2033年區域市場佔有率分析
  • 區域市場儀表板
  • 2021-2033 年市場規模與預測趨勢分析：
  • 北美洲
    • 按國家/地區，2021-2033 年
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第7章 競爭態勢

  • 參與者概覽
  • 企業市場分析
  • 公司分類
  • 戰略地圖
  • 公司簡介/上市公司
    • Pfizer Inc
    • Takeda Pharmaceutical Company Limited（Shire Plc）
    • Sanofi（Genzyme Corporation）
    • BioMarin
    • Johnson &Johnson（Actelion Pharmaceuticals Ltd）
    • Amicus Therapeutics, Inc
    • Alexion Pharmaceuticals, Inc
    • Sigilon Therapeutics, Inc
    • Orphazyme A/S
Product Code: GVR-4-68040-649-3

Lysosomal Storage Disease Treatment Market Summary

The global lysosomal storage disease treatment market size was estimated at USD 4.54 billion in 2024 and is projected to reach USD 6.68 billion by 2033, growing at a CAGR of 4.54% from 2025 to 2033, driven by rising diagnostic capabilities, advancements in enzyme replacement and gene therapies, and increased awareness of rare genetic disorders. The lysosomal storage disease (LSD) treatment market is experiencing steady growth due to expanding research and development initiatives and rising awareness about these rare genetic conditions.

Significant R&D investments have enhanced therapeutic advancements, helping address unmet medical needs. A study published by the National Library of Medicine in July 2022 noted that LSDs, as a group, are more prevalent than previously assumed, with a collective incidence ranging from 1 in 5,000 to 1 in 8,000 individuals. It also highlighted the influence of ethnicity and geography on disease prevalence. For instance, Gaucher disease appears in 1 in 40,000 to 60,000 people in the general population, while the rate increases to 1 in 800 among Ashkenazi Jews. Similarly, Tay-Sachs disease and Niemann-Pick A are more common in this demographic, while the Finnish population has a higher frequency of aspartylglucosaminuria at 1 in 18,500. These rising prevalence rates underscore the growing need for effective treatments, fueling market expansion.

The introduction of innovative therapies is expected to strengthen the LSD treatment market further. Companies actively pursue novel drug development, supported by increasing global R&D spending. For example, in February 2021, Genethon initiated a gene therapy clinical trial targeting late-onset Pompe disease in collaboration with Spark Therapeutics, utilizing proprietary technologies. In parallel, awareness campaigns have gained momentum, playing a vital role in improving patient outcomes. In countries like the U.S. and the UK, awareness of Fabry disease has significantly increased through initiatives like Fabry Disease Awareness Month, observed every April, as promoted by the National Fabry Disease Foundation (NFDF), Fabry International Network, Fabry Australia, and the UK's MPS Society.

Global Lysosomal Storage Disease Treatment Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global lysosomal storage disease treatment market report based on treatment type, disease type, and region:

  • Treatment Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Enzyme Replacement Therapy
    • Velaglucerase Alfa
    • Alglucosidase Alfa (Myozyme/Lumizyme)
    • Idursulfase (Elaprase)
    • Imiglucerase (Cerezyme)
    • Others
  • Substrate Reduction Therapy
  • Others
  • Disease Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Gaucher Disease
  • Mucopolysaccharidoses
  • Pompe Disease
  • Fabry Disease
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Treatment Type
    • 1.2.2. Disease Type
    • 1.2.3. Regional
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Lysosomal Storage Disease (LSDs) Treatment Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Lysosomal Storage Disease (LSDs) Treatment Market: Treatment Type Business Analysis

  • 4.1. Treatment Type Market Share, 2025 & 2033
  • 4.2. Treatment Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Treatment Type, 2021 to 2033 (USD Million)
  • 4.4. Enzyme Replacement Therapy
    • 4.4.1. Enzyme Replacement Therapy Market, 2021 - 2033 (USD Million)
    • 4.4.2. Velaglucerase Alfa
      • 4.4.2.1. Velaglucerase Alfa Market, 2021 - 2033 (USD Million)
    • 4.4.3. Alglucosidase Alfa (Myozyme/Lumizyme)
      • 4.4.3.1. Alglucosidase Alfa (Myozyme/Lumizyme) Market, 2021 - 2033 (USD Million)
    • 4.4.4. Idursulfase (Elaprase)
      • 4.4.4.1. Idursulfase (Elaprase) Market, 2021 - 2033 (USD Million)
    • 4.4.5. Imiglucerase (Cerezyme)
      • 4.4.5.1. Imiglucerase (Cerezyme) Market, 2021 - 2033 (USD Million)
    • 4.4.6. Others
      • 4.4.6.1. Others Market, 2021 - 2033 (USD Million)
  • 4.5. Substrate Reduction Therapy
    • 4.5.1. Substrate Reduction Therapy Market, 2021 - 2033 (USD Million)
    • 4.5.2. Others Market, 2021 - 2033 (USD Million)

Chapter 5. Lysosomal Storage Disease (LSDs) Treatment Market: Disease Type Business Analysis

  • 5.1. Disease Type Market Share, 2025 & 2033
  • 5.2. Disease Type Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Disease Type, 2021 to 2033 (USD Million)
  • 5.4. Gaucher Disease
    • 5.4.1. Gaucher Disease Market, 2021 - 2033 (USD Million)
  • 5.5. Mucopolysaccharidoses
    • 5.5.1. Mucopolysaccharidoses Market, 2021 - 2033 (USD Million)
  • 5.6. Pompe Disease
    • 5.6.1. Pompe Disease Market, 2021 - 2033 (USD Million)
  • 5.7. Fabry Disease
    • 5.7.1. Fabry Disease Market, 2021 - 2033 (USD Million)
  • 5.8. Others
    • 5.8.1. Others Market, 2021 - 2033 (USD Million)

Chapter 6. Lysosomal Storage Disease (LSDs) Treatment Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2025 & 2033
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 6.4. North America
    • 6.4.1. North America Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Target Disease Type Prevalence
      • 6.4.2.3. Regulatory Framework
      • 6.4.2.4. Reimbursement Framework
      • 6.4.2.5. U.S. Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Target Disease Type Prevalence
      • 6.4.3.3. Regulatory Framework
      • 6.4.3.4. Reimbursement Framework
      • 6.4.3.5. U.S. Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Target Disease Type Prevalence
      • 6.4.4.3. Regulatory Framework
      • 6.4.4.4. Reimbursement Framework
      • 6.4.4.5. Mexico Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Target Disease Type Prevalence
      • 6.5.2.3. Regulatory Framework
      • 6.5.2.4. Reimbursement Framework
      • 6.5.2.5. Uk Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Target Disease Type Prevalence
      • 6.5.3.3. Regulatory Framework
      • 6.5.3.4. Reimbursement Framework
      • 6.5.3.5. Germany Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Target Disease Type Prevalence
      • 6.5.4.3. Regulatory Framework
      • 6.5.4.4. Reimbursement Framework
      • 6.5.4.5. France Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Target Disease Type Prevalence
      • 6.5.5.3. Regulatory Framework
      • 6.5.5.4. Reimbursement Framework
      • 6.5.5.5. Italy Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Target Disease Type Prevalence
      • 6.5.6.3. Regulatory Framework
      • 6.5.6.4. Reimbursement Framework
      • 6.5.6.5. Spain Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.7. Denmark
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Target Disease Type Prevalence
      • 6.5.7.3. Regulatory Framework
      • 6.5.7.4. Reimbursement Framework
      • 6.5.7.5. Denmark Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.8. Sweden
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Target Disease Type Prevalence
      • 6.5.8.3. Regulatory Framework
      • 6.5.8.4. Reimbursement Framework
      • 6.5.8.5. Sweden Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.9. Norway
      • 6.5.9.1. Key Country Dynamics
      • 6.5.9.2. Target Disease Type Prevalence
      • 6.5.9.3. Regulatory Framework
      • 6.5.9.4. Reimbursement Framework
      • 6.5.9.5. Norway Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Target Disease Type Prevalence
      • 6.6.2.3. Regulatory Framework
      • 6.6.2.4. Reimbursement Framework
      • 6.6.2.5. Japan Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Target Disease Type Prevalence
      • 6.6.3.3. Regulatory Framework
      • 6.6.3.4. Reimbursement Framework
      • 6.6.3.5. China Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Target Disease Type Prevalence
      • 6.6.4.3. Regulatory Framework
      • 6.6.4.4. Reimbursement Framework
      • 6.6.4.5. India Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.5. Australia
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Target Disease Type Prevalence
      • 6.6.5.3. Regulatory Framework
      • 6.6.5.4. Reimbursement Framework
      • 6.6.5.5. Australia Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.6. South Korea
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Target Disease Type Prevalence
      • 6.6.6.3. Regulatory Framework
      • 6.6.6.4. Reimbursement Framework
      • 6.6.6.5. South Korea Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.7. Thailand
      • 6.6.7.1. Key Country Dynamics
      • 6.6.7.2. Target Disease Type Prevalence
      • 6.6.7.3. Regulatory Framework
      • 6.6.7.4. Reimbursement Framework
      • 6.6.7.5. Thailand Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Target Disease Type Prevalence
      • 6.7.2.3. Regulatory Framework
      • 6.7.2.4. Reimbursement Framework
      • 6.7.2.5. Japan Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Target Disease Type Prevalence
      • 6.7.3.3. Regulatory Framework
      • 6.7.3.4. Reimbursement Framework
      • 6.7.3.5. China Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8. Middle East and Africa
    • 6.8.1. Middle East and Africa Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2017 - 2033 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Target Disease Type Prevalence
      • 6.8.2.3. Regulatory Framework
      • 6.8.2.4. Reimbursement Framework
      • 6.8.2.5. South Africa Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Target Disease Type Prevalence
      • 6.8.3.3. Regulatory Framework
      • 6.8.3.4. Reimbursement Framework
      • 6.8.3.5. Saudi Arabia Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Target Disease Type Prevalence
      • 6.8.4.3. Regulatory Framework
      • 6.8.4.4. Reimbursement Framework
      • 6.8.4.5. UAE Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Target Disease Type Prevalence
      • 6.8.5.3. Regulatory Framework
      • 6.8.5.4. Reimbursement Framework
      • 6.8.5.5. Kuwait Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. Pfizer Inc
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Treatment Type Benchmarking
      • 7.5.1.4. Strategic Initiatives
    • 7.5.2. Takeda Pharmaceutical Company Limited (Shire Plc)
      • 7.5.2.1. Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Treatment Type Benchmarking
      • 7.5.2.4. Strategic Initiatives
    • 7.5.3. Sanofi (Genzyme Corporation)
      • 7.5.3.1. Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Treatment Type Benchmarking
      • 7.5.3.4. Strategic Initiatives
    • 7.5.4. BioMarin
      • 7.5.4.1. Overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Treatment Type Benchmarking
      • 7.5.4.4. Strategic Initiatives
    • 7.5.5. Johnson & Johnson (Actelion Pharmaceuticals Ltd)
      • 7.5.5.1. Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Treatment Type Benchmarking
      • 7.5.5.4. Strategic Initiatives
    • 7.5.6. Amicus Therapeutics, Inc
      • 7.5.6.1. Overview
      • 7.5.6.2. Financial Performance
      • 7.5.6.3. Treatment Type Benchmarking
      • 7.5.6.4. Strategic Initiatives
    • 7.5.7. Alexion Pharmaceuticals, Inc
      • 7.5.7.1. Overview
      • 7.5.7.2. Financial Performance
      • 7.5.7.3. Treatment Type Benchmarking
      • 7.5.7.4. Strategic Initiatives
    • 7.5.8. Sigilon Therapeutics, Inc
      • 7.5.8.1. Overview
      • 7.5.8.2. Financial Performance
      • 7.5.8.3. Treatment Type Benchmarking
      • 7.5.8.4. Strategic Initiatives
    • 7.5.9. Orphazyme A/S
      • 7.5.9.1. Overview
      • 7.5.9.2. Financial Performance
      • 7.5.9.3. Treatment Type Benchmarking
      • 7.5.9.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global lysosomal storage disease (LSDs) treatment market, by region, 2021 - 2033 (USD Million)
  • Table 4 Global lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 5 Global lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
  • Table 6 North America lysosomal storage disease (LSDs) treatment market, by country, 2021 - 2033 (USD Million)
  • Table 7 North America lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 8 North America lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
  • Table 9 U.S. lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 10 U.S. lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
  • Table 11 Canada lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 12 Canada lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
  • Table 13 Mexico lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 14 Mexico lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
  • Table 15 Europe lysosomal storage disease (LSDs) treatment market, by country, 2021 - 2033 (USD Million)
  • Table 16 Europe lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 17 Europe lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
  • Table 18 UK lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 19 UK lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
  • Table 20 Germany lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 21 Germany lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
  • Table 22 France lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 23 France lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
  • Table 24 Italy lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 25 Italy lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
  • Table 26 Spain lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 27 Spain lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
  • Table 28 Norway lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 29 Norway lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
  • Table 30 Denmark lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 31 Denmark lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
  • Table 32 Sweden lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 33 Sweden lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
  • Table 34 Asia Pacific lysosomal storage disease (LSDs) treatment market, by country, 2021 - 2033 (USD Million)
  • Table 35 Asia Pacific lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 36 Asia Pacific lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
  • Table 37 Japan lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 38 Japan lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
  • Table 39 China lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 40 China lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
  • Table 41 India lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 42 India lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
  • Table 43 Australia lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 44 Australia lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
  • Table 45 South Korea lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 46 South Korea lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
  • Table 47 Thailand lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 48 Thailand lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
  • Table 49 Latin America lysosomal storage disease (LSDs) treatment market, by country, 2021 - 2033 (USD Million)
  • Table 50 Latin America lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 51 Latin America lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
  • Table 52 Brazil lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 53 Brazil lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
  • Table 54 Argentina lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 55 Argentina lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
  • Table 56 Middle East & Africa Lysosomal storage disease (LSDs) treatment market, by country, 2021 - 2033 (USD Million)
  • Table 57 Middle East & Africa lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 58 Middle East & Africa lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
  • Table 59 South Africa lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 60 South Africa lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
  • Table 61 Saudi Arabia lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 62 Saudi Arabia lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
  • Table 63 UAE lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 64 UAE lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
  • Table 65 Kuwait lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 66 Kuwait lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Lysosomal storage disease (LSDs) treatment market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapeutic approach and disease type outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Lysosomal storage disease (LSDs) treatment market dynamics
  • Fig. 12 Lysosomal storage disease (LSDs) treatment market: Porter's five forces analysis
  • Fig. 13 Lysosomal storage disease (LSDs) treatment market: PESTLE analysis
  • Fig. 14 Treatment Type market, 2021 - 2033 (USD Million)
  • Fig. 15 Enzyme Replacement Therapy market, 2021 - 2033 (USD Million)
  • Fig. 16 Velaglucerase Alfa market, 2021 - 2033 (USD Million)
  • Fig. 17 Alglucosidase Alfa (Myozyme/Lumizyme) market, 2021 - 2033 (USD Million)
  • Fig. 18 Idursulfase (Elaprase) market, 2021 - 2033 (USD Million)
  • Fig. 19 Imiglucerase (Cerezyme) market, 2021 - 2033 (USD Million)
  • Fig. 20 Others market, 2021 - 2033 (USD Million)
  • Fig. 21 Substrate reduction therapy market, 2021 - 2033 (USD Million)
  • Fig. 22 Others market, 2021 - 2033 (USD Million)
  • Fig. 23 Disease Type market, 2021 - 2033 (USD Million)
  • Fig. 24 Gaucher disease market, 2021 - 2033 (USD Million)
  • Fig. 25 Mucopolysaccharidoses market, 2021 - 2033 (USD Million)
  • Fig. 26 Pompe disease market, 2021 - 2033 (USD Million)
  • Fig. 27 Fabry disease market, 2021 - 2033 (USD Million)
  • Fig. 28 Others market, 2021 - 2033 (USD Million)
  • Fig. 29 Lysosomal storage disease (LSDs) treatment market revenue, by region
  • Fig. 30 Regional marketplace: Key takeaways
  • Fig. 31 North America lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
  • Fig. 32 U.S. country dynamics
  • Fig. 33 U.S. lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
  • Fig. 34 Canada country dynamics
  • Fig. 35 Canada lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
  • Fig. 36 Mexico country dynamics
  • Fig. 37 Mexico lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
  • Fig. 38 Europe lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
  • Fig. 39 UK country dynamics
  • Fig. 40 UK lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
  • Fig. 41 Germany country dynamics
  • Fig. 42 Germany lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
  • Fig. 43 France country dynamics
  • Fig. 44 France lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
  • Fig. 45 Italy country dynamics
  • Fig. 46 Italy lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
  • Fig. 47 Spain country dynamics
  • Fig. 48 Spain lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
  • Fig. 49 Norway country dynamics
  • Fig. 50 Norway lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
  • Fig. 51 Sweden country dynamics
  • Fig. 52 Sweden lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
  • Fig. 53 Denmark country dynamics
  • Fig. 54 Denmark lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
  • Fig. 55 Asia Pacific lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
  • Fig. 56 Japan country dynamics
  • Fig. 57 Japan lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
  • Fig. 58 China country dynamics
  • Fig. 59 China lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
  • Fig. 60 India country dynamics
  • Fig. 61 India lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
  • Fig. 62 Australia country dynamics
  • Fig. 63 Australia lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
  • Fig. 64 South Korea country dynamics
  • Fig. 65 South Korea lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
  • Fig. 66 Thailand country dynamics
  • Fig. 67 Thailand lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
  • Fig. 68 Latin America lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
  • Fig. 69 Brazil country dynamics
  • Fig. 70 Brazil lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
  • Fig. 71 Argentina country dynamics
  • Fig. 72 Argentina lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
  • Fig. 73 MEA lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
  • Fig. 74 South Africa country dynamics
  • Fig. 75 South Africa lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
  • Fig. 76 Saudi Arabia country dynamics
  • Fig. 77 Saudi Arabia lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
  • Fig. 78 UAE country dynamics
  • Fig. 79 UAE lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
  • Fig. 80 Kuwait country dynamics
  • Fig. 81 Kuwait lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
  • Fig. 82 Company categorization
  • Fig. 83 Company market position analysis
  • Fig. 84 Strategic framework